Company Profile
Annexon, Inc. Stock Price, News & Catalysts
- Ticker:
- ANNX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.17 USD (+6.11%)
Close
Last updated: September 17, 2026
862M USD
Market cap
Why the stock is moving
Following the latest company update, “Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)”, ANNX closed up 6.11% at $4.17 on Sep 17, 2026. The move occurred in the trading session associated with this company update.
Company overview
Classical Complement Inhibition
Annexon develops therapies that inhibit the classical complement pathway, which can drive harmful inflammation and tissue damage in neurologic, ophthalmic, and autoimmune diseases.
Tanruprubart
Tanruprubart is an antibody therapy for Guillain-Barré syndrome. Its European marketing application is under review, and Annexon is preparing a U.S. biologics license application supported by clinical and real-world evidence.
Vonaprument
Vonaprument is a complement inhibitor in the pivotal Phase 3 ARCHER II study for geographic atrophy, an advanced form of dry age-related macular degeneration. The program aims to preserve vision by blocking upstream complement activation.
ANX1502
ANX1502 is an oral C1s inhibitor intended to extend classical-complement modulation into chronic autoimmune diseases. A proof-of-concept study is evaluating the candidate in cold agglutinin disease.
Future catalysts
- Proof-of-concept update for ANX1502 in cold agglutinin disease in fall 2026.
- Month 15 primary-endpoint results from the Phase 3 ARCHER II study of vonaprument in the fourth quarter of 2026.
- Submission of a BLA for tanruprubart in Guillain-Barré syndrome in the fourth quarter of 2026.
- Completion of ARCHER II, including the Month 24 primary endpoint, in the third quarter of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Annexon, Inc. (ANNX)?
Annexon, Inc. (ANNX) most recently closed at 4.17 USD, a +6.11% move versus the previous session.
What is the market cap of Annexon, Inc. (ANNX)?
Annexon, Inc. currently has a market capitalization of 862M USD on BioPharmSignal.
What does Annexon, Inc. do?
Classical Complement Inhibition Annexon develops therapies that inhibit the classical complement pathway, which can drive harmful inflammation and tissue damage in neurologic, ophthalmic, and autoimmune diseases. Tanruprubart Tanruprubart is an antibody therapy for Guillain-Barré syndrome. Its European marketing application is under review, and Annexon is...
On which exchange is ANNX stock listed?
Annexon, Inc. (ANNX) is associated with NASDAQ, United States, Biopharma.
What is proof-of-concept?
Proof-of-concept update for ANX1502 in cold agglutinin disease in fall 2026.
Which conditions is Annexon, Inc. targeting with proof-of-concept?
Annexon, Inc. is associated with inflammatory disease based on its company overview and current catalyst commentary.
How does Annexon, Inc. describe recent progress with proof-of-concept?
Proof-of-concept update for ANX1502 in cold agglutinin disease in fall 2026.
What is of-concept?
A proof-of-concept study is evaluating the candidate in cold agglutinin disease.